Skip to content

Comparison of Effect of Dexmedetomidine and Midazolam on Emergence Agitation

Comparison of Effect of Dexmedetomidine and Midazolam on Emergence Agitation in Patients Undergoing Functional Endoscopic Sinus Surgery

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07392983
Enrollment
146
Registered
2026-02-06
Start date
2025-07-01
Completion date
2025-12-31
Last updated
2026-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Emergence Agitation

Brief summary

Since the frequency of emergence agitation (EA) is relatively high in children while undergoing nasal surgery, and there is not much data available in Pakistan regarding EA in adults undergoing functional endoscopic sinus surgery (FESS). Hence there is a need to conduct this study in the local population to see the effect of dexmedetomidine and midazolam on EA. Therefore, the current study was initiated, aiming to compare the effect of dexmedetomidine and midazolam on EA in patients undergoing FESS.

Detailed description

There is not much local data present on the topic of EA. As the frequency of EA is relatively high, it can lead to any unwanted event, which can lead to other complications in the patients undergoing nasal surgery. Although in some studies dexmedetomidine has been found to significantly reduce the frequency of EA and severity, provide better sedation, and lower the need for postoperative rescue analgesia in patients undergoing FESS, few others have claimed comparable results for midazolam as well. The findings of this study would not only add to the local data but also be helpful in determining a better option in reducing the frequency of this phenomenon in patients undergoing FESS under general anesthesia.

Interventions

DRUGDexmedetomidine

Patients were given dexmedetomidine injection with a loading dose of 1 µg/kg in 10 minute prior to the procedure.

DRUGMidazolam

Patients received midazolam with a loading dose of 0.02 mg/kg in 10 min prior to the procedure.

Sponsors

Muhammad Aamir Latif
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
16 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Any gender * Aged 16-60 years * Undergoing elective FESS under general anesthesia

Exclusion criteria

* Patients with the presence of infection at the site of the blockage * Epilepsy, myasthenia gravis, or polio (as per history and clinical record) * Systemic illness (such as cardiac, hepatic, endocrinal or neurological) * Substance induced disorder * Psychiatric disorders * Taking medications, such as alpha 2 agonists, beta blockers' or tricyclic anti-depressants * Allergies to the medications used

Design outcomes

Primary

MeasureTime frameDescription
Effectiveness in emergence agitation90 minutesThe effectiveness of the treatment was assessed through Ricker's sedation and agitation score, with a score of 4 as efficacy 'yes'.

Countries

Pakistan

Contacts

PRINCIPAL_INVESTIGATORMadiha Ashraf

Bahawal Victoria Hospital/Quid-e-Azam Medical College, Bahawalpur

STUDY_DIRECTORAmbreen Khan, FCPS

Bahawal Victoria Hospital/Quid-e-Azam Medical College, Bahawalpur

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026